{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T16:02:06Z","timestamp":1782144126232,"version":"3.54.5"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Egypt Natl Canc Inst"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction and background<\/jats:title>\n            <jats:p>Non-small cell lung cancer (NSCLC) is the third most common type of cancer in Palestine and has the highest mortality rate. Treatment approaches for NSCLC depend on many factors including stage, histology, molecular profile, and patient performance status.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Objectives<\/jats:title>\n            <jats:p>This study explored the patient characteristics, molecular profiles, metastatic sites, prognosis, and treatment modalities.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This observational retrospective cohort study was conducted at multiple Palestinian hospitals. This study included patients diagnosed with metastatic NSCLC between 2016 and 2022. Patients with small-cell lung cancer (SCLC), newly diagnosed lung cancer, or incomplete information were excluded from the study. Patient data were obtained from the date of lung cancer diagnosis until death or loss to follow-up. Data were analyzed using IBM SPSS, and overall survival was calculated using the Kaplan\u2013Meier estimate.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The study included 102 patients, 80.4% were male, 40.2% were current smokers, 42.2% were ex-smokers, and 17.6% were nonsmokers.\u00a0(86.35%) of the patients were diagnosed with adenocarcinoma, and\u00a0(77.5%) were diagnosed with stage IV NSCLC. Tumor recurrence was observed in 47.1% of patients after surgery. A total of 56.9% had PDL-1 expression\u2009\u2265\u200910%, and 45.1% had EGFR mutations. Fourteen (13.7%) received mono-chemotherapy with an estimated OS of (1219.200) days, 34 (33.3%) received mono-immunotherapy with an estimated OS of (720.152) days, and 54 (52.9%) received a combination of chemotherapy and immunotherapy with an OS of 2006.777\u00a0days. PFS (&gt;\u20091\u00a0year) was higher in patients receiving combination therapy (58.3%). Myelosuppression, renal damage, and liver damage are some of the major side effects experienced by patients receiving either type of treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The findings of this study provide vital information on tumor molecular mutation patterns and PDL expression for the adoption of appropriate measures in prevention and treatment strategies for NSCLC in Palestine. The majority of patients diagnosed with NSCLC were males with a history of smoking and were diagnosed at an advanced stage, which requires increased education, wariness of lung cancer, and smoking cessation programs at the national level.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s43046-025-00298-8","type":"journal-article","created":{"date-parts":[[2025,7,13]],"date-time":"2025-07-13T23:02:18Z","timestamp":1752447738000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Non-small cell lung cancer (NSCLC): characteristics, risk factors, molecular profile patterns, and treatment \u2014 a retrospective cohort study from Palestine"],"prefix":"10.1186","volume":"37","author":[{"given":"Abdallah Damin","family":"Abukhalil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaldieh","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wardah","family":"Alhaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inas","family":"Salah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousef","family":"Sahoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ni\u2019meh","family":"Al-Shami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Qawasmeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,14]]},"reference":[{"key":"298_CR1","doi-asserted-by":"publisher","unstructured":"Halahleh K, Abu-Rmeileh NME, Abusrour MM. General oncology care in Palestine. In: Cancer in the Arab World. 2022. \nhttps:\/\/doi.org\/10.1007\/978-981-16-7945-2_13.","DOI":"10.1007\/978-981-16-7945-2_13"},{"key":"298_CR2","doi-asserted-by":"publisher","unstructured":"Ruiz-Cordero R, Devine WP. Targeted therapy and checkpoint immunotherapy in lung cancer. Surg Pathol Clin. 2020;13(1). \nhttps:\/\/doi.org\/10.1016\/j.path.2019.11.002.","DOI":"10.1016\/j.path.2019.11.002"},{"key":"298_CR3","doi-asserted-by":"publisher","unstructured":"Alexander M, Kim SY, Cheng H. Update 2020: management of non-small cell lung cancer. Lung. 2020;198(6). \nhttps:\/\/doi.org\/10.1007\/s00408-020-00407-5.","DOI":"10.1007\/s00408-020-00407-5"},{"key":"298_CR4","doi-asserted-by":"publisher","unstructured":"Waterhouse D, Lam J, Betts KA, et al. Real-world outcomes of immunotherapy\u2013based regimens in first-line advanced non-small cell lung cancer. Lung Cancer. 2021;156. \nhttps:\/\/doi.org\/10.1016\/j.lungcan.2021.04.007.","DOI":"10.1016\/j.lungcan.2021.04.007"},{"key":"298_CR5","doi-asserted-by":"publisher","unstructured":"Duma N, Santana-Davila R, Molina JR. Non\u2013small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc. 2019;94(8). \nhttps:\/\/doi.org\/10.1016\/j.mayocp.2019.01.013.","DOI":"10.1016\/j.mayocp.2019.01.013"},{"key":"298_CR6","volume-title":"Non-small cell lung cancer treatment \u2013 Health Professional Version (PDQ\u00ae)","author":"J Dancey","year":"2016","unstructured":"Dancey J, Forde P, Mak R, Rajan A, Szabo E. Non-small cell lung cancer treatment \u2013 Health Professional Version (PDQ\u00ae). National Cancer Institute: Published online; 2016."},{"key":"298_CR7","doi-asserted-by":"publisher","unstructured":"Nagasaka M, Gadgeel SM. Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer. Expert Rev Anticancer Ther. 2018;18(1). \nhttps:\/\/doi.org\/10.1080\/14737140.2018.1409624.","DOI":"10.1080\/14737140.2018.1409624"},{"key":"298_CR8","doi-asserted-by":"publisher","unstructured":"Ettinger DS, Wood DE, Aisner DL, et al. Non\u2013small cell lung cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2022;20(5). \nhttps:\/\/doi.org\/10.6004\/jnccn.2022.0025.","DOI":"10.6004\/jnccn.2022.0025"},{"key":"298_CR9","doi-asserted-by":"publisher","unstructured":"Mitwalli S, Hammoudeh W, Giacaman R, Harding R. Access to advanced cancer care services in the West Bank-occupied Palestinian territory. Front Oncol. 2023;13. \nhttps:\/\/doi.org\/10.3389\/fonc.2023.1120783.","DOI":"10.3389\/fonc.2023.1120783"},{"issue":"4","key":"298_CR10","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.cllc.2022.02.002","volume":"23","author":"AR Jazieh","year":"2022","unstructured":"Jazieh AR, Sa\u011flam EK, \u00d6nal HC, et al. Real-world treatment patterns and outcomes in stage III non-small cell lung cancer: Middle East and Africa \u2013 KINDLE study. Clin Lung Cancer. 2022;23(4):364\u201373. https:\/\/doi.org\/10.1016\/j.cllc.2022.02.002.","journal-title":"Clin Lung Cancer"},{"key":"298_CR11","doi-asserted-by":"publisher","unstructured":"Halahleh K, Abu-Rmeileh NME, Abusrour MM. General oncology care in Palestine. In: Cancer in the Arab World. Springer Singapore; 2022:195\u2013213. \nhttps:\/\/doi.org\/10.1007\/978-981-16-7945-2_13.","DOI":"10.1007\/978-981-16-7945-2_13"},{"key":"298_CR12","doi-asserted-by":"publisher","unstructured":"Seir RA, Kharroubi A, Ghannam I. Prevalence of tobacco use among young adults in Palestine. Eastern Mediterranean Health Journal. 2020;26(1). \nhttps:\/\/doi.org\/10.26719\/2020.26.1.75.","DOI":"10.26719\/2020.26.1.75"},{"key":"298_CR13","doi-asserted-by":"publisher","unstructured":"Walser T, Cui X, Yanagawa J, et al. Smoking and lung cancer: the role of inflammation. In: Proceedings of the American Thoracic Society. Vol 5. ; 2008. \nhttps:\/\/doi.org\/10.1513\/pats.200809-100TH.","DOI":"10.1513\/pats.200809-100TH"},{"key":"298_CR14","doi-asserted-by":"publisher","unstructured":"Caini S, Del Riccio M, Vettori V, et al. Quitting smoking at or around diagnosis improves the overall survival of lung cancer patients: a systematic review and meta-analysis. Journal of Thoracic Oncology. 2022;17(5). \nhttps:\/\/doi.org\/10.1016\/j.jtho.2021.12.005.","DOI":"10.1016\/j.jtho.2021.12.005"},{"key":"298_CR15","doi-asserted-by":"publisher","unstructured":"ALQudah MA, ALFaqih MA, Hamouri S, et al. Epidemiology and histopathological classification of lung cancer: a study from Jordan, retrospective observational study. Annals of Medicine and Surgery. 2021;65. \nhttps:\/\/doi.org\/10.1016\/j.amsu.2021.102330.","DOI":"10.1016\/j.amsu.2021.102330"},{"issue":"2","key":"298_CR16","first-page":"492","volume":"118","author":"L Miron","year":"2014","unstructured":"Miron L, Bosanceanu M, Filimon R, Petrariu FD. Clinical-epidemiological study on advanced non-small cell lung cancer. Rev Med Chir Soc Med Nat Iasi. 2014;118(2):492\u20136.","journal-title":"Rev Med Chir Soc Med Nat Iasi"},{"key":"298_CR17","doi-asserted-by":"publisher","first-page":"205031212110437","DOI":"10.1177\/20503121211043709","volume":"9","author":"G Fakhri","year":"2021","unstructured":"Fakhri G, Akel R, Khalifeh I, et al. Prevalence of programmed death ligand-1 in patients diagnosed with non-small cell lung cancer in Lebanon. SAGE Open Med. 2021;9:205031212110437. https:\/\/doi.org\/10.1177\/20503121211043709.","journal-title":"SAGE Open Med"},{"key":"298_CR18","doi-asserted-by":"publisher","unstructured":"Shiravand Y, Khodadadi F, Kashani SMA, et al. Immune checkpoint inhibitors in cancer therapy. Current Oncology. 2022;29(5). \nhttps:\/\/doi.org\/10.3390\/curroncol29050247.","DOI":"10.3390\/curroncol29050247"},{"key":"298_CR19","doi-asserted-by":"publisher","unstructured":"Zheng Y, Fang YC, Li J. PD-L1 expression levels on tumor cells affect their immunosuppressive activity. Oncol Lett. 2019;18(5). \nhttps:\/\/doi.org\/10.3892\/ol.2019.10903.","DOI":"10.3892\/ol.2019.10903"},{"key":"298_CR20","doi-asserted-by":"publisher","unstructured":"Chen S, Zhang Z, Zheng X, et al. Response efficacy of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. Front Oncol. 2021;11. \nhttps:\/\/doi.org\/10.3389\/fonc.2021.562315.","DOI":"10.3389\/fonc.2021.562315"},{"key":"298_CR21","doi-asserted-by":"publisher","unstructured":"Matos JNCM, Sousa SR, Figueiredo AM, Pego A, Barata F. Impact of PD-L1 expression levels on the response to pembrolizumab in metastatic non-small cell lung cancer>. In: ; 2021. \nhttps:\/\/doi.org\/10.1183\/13993003.congress-2021.pa2189.","DOI":"10.1183\/13993003.congress-2021.pa2189"},{"key":"298_CR22","doi-asserted-by":"publisher","unstructured":"Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions. Mol Cancer. 2022;21(1). \nhttps:\/\/doi.org\/10.1186\/s12943-021-01489-2.","DOI":"10.1186\/s12943-021-01489-2"},{"issue":"1","key":"298_CR23","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1186\/s12885-018-4774-y","volume":"18","author":"Z Benbrahim","year":"2018","unstructured":"Benbrahim Z, Antonia T, Mellas N. EGFR mutation frequency in Middle East and African non-small cell lung cancer patients: a systematic review and meta-analysis. BMC Cancer. 2018;18(1):891. https:\/\/doi.org\/10.1186\/s12885-018-4774-y.","journal-title":"BMC Cancer"},{"issue":"11","key":"298_CR24","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1016\/j.jtho.2019.02.016","volume":"14","author":"AR Jazieh","year":"2019","unstructured":"Jazieh AR, Algwaiz G, Errihani H, et al. Lung cancer in the Middle East and North Africa region. J Thorac Oncol. 2019;14(11):1884\u201391. https:\/\/doi.org\/10.1016\/j.jtho.2019.02.016.","journal-title":"J Thorac Oncol"},{"key":"298_CR25","doi-asserted-by":"publisher","unstructured":"Yoneda K, Imanishi N, Ichiki Y, Tanaka F. Treatment of non-small cell lung cancer with EGFR-mutations. J UOEH. 2019;41(2). \nhttps:\/\/doi.org\/10.7888\/juoeh.41.153.","DOI":"10.7888\/juoeh.41.153"},{"key":"298_CR26","doi-asserted-by":"publisher","unstructured":"Ruiz-Pati\u00f1o A, Arrieta O, Cardona AF, et al. Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (Quijote-CLICaP). Thorac Cancer. 2020;11(2). \nhttps:\/\/doi.org\/10.1111\/1759-7714.13272.","DOI":"10.1111\/1759-7714.13272"},{"key":"298_CR27","doi-asserted-by":"publisher","unstructured":"Prigerson HG, Bao Y, Shah MA, et al. Chemotherapy use, performance status, and quality of life at the end of life. JAMA Oncol. 2015;1(6). \nhttps:\/\/doi.org\/10.1001\/jamaoncol.2015.2378.","DOI":"10.1001\/jamaoncol.2015.2378"},{"key":"298_CR28","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.32390","author":"GF Fragkiadakis","year":"2022","unstructured":"Fragkiadakis GF, Spiliotopoulou M. Investigating the quality of life for cancer patients and estimating the cost of immunotherapy in selected cases. Cureus Published online. 2022. https:\/\/doi.org\/10.7759\/cureus.32390.","journal-title":"Cureus Published online"},{"issue":"3","key":"298_CR29","doi-asserted-by":"publisher","first-page":"288","DOI":"10.21037\/TLCR.2016.06.07","volume":"5","author":"C Zappa","year":"2016","unstructured":"Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016;5(3):288\u2013300. https:\/\/doi.org\/10.21037\/TLCR.2016.06.07.","journal-title":"Transl Lung Cancer Res"},{"key":"298_CR30","doi-asserted-by":"publisher","unstructured":"Lackey A, Donington J. Surgical management of lung cancer. Semin Intervent Radiol. 2013;30(2). \nhttps:\/\/doi.org\/10.1055\/s-0033-1342954.","DOI":"10.1055\/s-0033-1342954"},{"issue":"9","key":"298_CR31","first-page":"3953","volume":"32","author":"H Uramoto","year":"2012","unstructured":"Uramoto H, Tanaka F. Prediction of recurrence after complete resection in patients with NSCLC. Anticancer Res. 2012;32(9):3953\u201360.","journal-title":"Anticancer Res"},{"key":"298_CR32","doi-asserted-by":"publisher","unstructured":"Masago K, Seto K, Fujita S, Sasaki E, Hosoda W, Kuroda H. Long-term recurrence of completely resected NSCLC. JTO Clin Res Rep. 2020;1(3). \nhttps:\/\/doi.org\/10.1016\/j.jtocrr.2020.100076.","DOI":"10.1016\/j.jtocrr.2020.100076"},{"key":"298_CR33","doi-asserted-by":"publisher","unstructured":"Rekulapelli A, E. Flausino L, Iyer G, Balkrishnan R. Effectiveness of immunological agents in non-small cell lung cancer. Cancer Rep. 2023;6(1). \nhttps:\/\/doi.org\/10.1002\/cnr2.1739.","DOI":"10.1002\/cnr2.1739"},{"key":"298_CR34","doi-asserted-by":"publisher","unstructured":"Ning X, Yu Y, Shao S, et al. The prospect of immunotherapy combined with chemotherapy in patients with advanced non-small cell lung cancer: a narrative review. Ann Transl Med. 2021;9(22). \nhttps:\/\/doi.org\/10.21037\/atm-21-4878.","DOI":"10.21037\/atm-21-4878"},{"key":"298_CR35","doi-asserted-by":"publisher","unstructured":"Le T, Gerber DE. Newer-generation EGFR inhibitors in lung cancer: how are they best used? Cancers (Basel). 2019;11(3). \nhttps:\/\/doi.org\/10.3390\/cancers11030366.","DOI":"10.3390\/cancers11030366"},{"issue":"2","key":"298_CR36","first-page":"39","volume":"26","author":"R Rimawi","year":"2024","unstructured":"Rimawi R, Wispelwey B, Madani N. Roadblocks to cancer care in the occupied Palestinian territories. Health Hum Rights. 2024;26(2):39\u201344.","journal-title":"Health Hum Rights"},{"issue":"1","key":"298_CR37","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3892\/mco.2014.410","volume":"3","author":"T Tamura","year":"2015","unstructured":"Tamura T, Kurishima K, Nakazawa K, et al. Specific organ metastases and survival in metastatic non-small-cell lung cancer. Mol Clin Oncol. 2015;3(1):217\u201321. https:\/\/doi.org\/10.3892\/mco.2014.410.","journal-title":"Mol Clin Oncol"},{"key":"298_CR38","doi-asserted-by":"publisher","unstructured":"Del Conte A, De Carlo E, Bertoli E, et al. Bone metastasis and immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): microenvironment and possible clinical implications. Int J Mol Sci. 2022;23(12). \nhttps:\/\/doi.org\/10.3390\/ijms23126832.","DOI":"10.3390\/ijms23126832"},{"key":"298_CR39","doi-asserted-by":"publisher","unstructured":"Nasr L, Diab S, Ghoche A, Yehia I, Nasr F louis. Real-world outcomes of immunotherapy regimens in first line non small cell lung cancer in lebanese patients. Journal of Clinical Oncology. 2022;40(16_suppl). \nhttps:\/\/doi.org\/10.1200\/jco.2022.40.16_suppl.e18741.","DOI":"10.1200\/jco.2022.40.16_suppl.e18741"},{"key":"298_CR40","doi-asserted-by":"publisher","unstructured":"Lumbard K, Keefer LA, van\u2019t erve I, et al. Abstract 2224: DELFI as a real-time treatment response assessment for patients with cancer. Cancer Res. 2022;82(12_Supplement). \nhttps:\/\/doi.org\/10.1158\/1538-7445.am2022-2224.","DOI":"10.1158\/1538-7445.am2022-2224"},{"key":"298_CR41","doi-asserted-by":"publisher","unstructured":"Aoki T, Akiba T, Nishiyama J, et al. Analysis of key clinical features for achieving complete remission in stage III and IV non-small cell lung cancer patients. Respir Res. 2019;20(1). \nhttps:\/\/doi.org\/10.1186\/s12931-019-1235-3.","DOI":"10.1186\/s12931-019-1235-3"},{"key":"298_CR42","doi-asserted-by":"publisher","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non\u2013small-cell lung cancer. New England Journal of Medicine. 2018;378(22). \nhttps:\/\/doi.org\/10.1056\/nejmoa1801005.","DOI":"10.1056\/nejmoa1801005"},{"key":"298_CR43","doi-asserted-by":"publisher","DOI":"10.18053\/jctres.07.202101.001","author":"Immunotherapy in non-small cell lung cancer","year":"2021","unstructured":"Immunotherapy in non-small cell lung cancer. update and new insights. J Clin Transl Res Published online. 2021. https:\/\/doi.org\/10.18053\/jctres.07.202101.001.","journal-title":"J Clin Transl Res Published online"},{"key":"298_CR44","doi-asserted-by":"publisher","unstructured":"Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non\u2013small-cell lung cancer. New England Journal of Medicine. 2018;379(21). \nhttps:\/\/doi.org\/10.1056\/nejmoa1810865.","DOI":"10.1056\/nejmoa1810865"},{"key":"298_CR45","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2022.2116005","author":"B Abdelazeem","year":"2022","unstructured":"Abdelazeem B, Abbas KS, Labieb F, et al. The role of immunotherapy plus chemotherapy versus chemotherapy alone as first-line treatment for advanced non-small cell lung cancer: an updated systematic review and meta-analysis of randomized controlled trials. Expert Rev Anticancer Ther Published online. 2022. https:\/\/doi.org\/10.1080\/14737140.2022.2116005.","journal-title":"Expert Rev Anticancer Ther Published online"},{"key":"298_CR46","doi-asserted-by":"publisher","unstructured":"Chen Q, Zhang Z, Li X, Bu L. Chemotherapy combined with immunotherapy as a first-line treatment brings benefits to patients with lung squamous cell carcinoma but different risks of adverse reactions: a systematic review and meta-analysis. Front Pharmacol. 2022;13. \nhttps:\/\/doi.org\/10.3389\/fphar.2022.940567.","DOI":"10.3389\/fphar.2022.940567"},{"issue":"21","key":"298_CR47","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1200\/JCO.21.00174","volume":"39","author":"M Reck","year":"2021","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, et al. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non\u2013small-cell lung cancer with PD-L1 tumor proportion score \u2265 50%. J Clin Oncol. 2021;39(21):2339\u201349. https:\/\/doi.org\/10.1200\/JCO.21.00174.","journal-title":"J Clin Oncol"},{"key":"298_CR48","doi-asserted-by":"publisher","unstructured":"Hauner K, Maisch P, Retz M. Nebenwirkungen der Chemotherapie. Urologe . 2017;56(4). \nhttps:\/\/doi.org\/10.1007\/s00120-017-0338-z.","DOI":"10.1007\/s00120-017-0338-z"},{"key":"298_CR49","volume-title":"Understanding immunotherapy side effects","author":"TE Leana Huntley","year":"2020","unstructured":"Leana Huntley TE. Understanding immunotherapy side effects. NCCN Guidlelines for Patients: Published online; 2020."},{"key":"298_CR50","doi-asserted-by":"publisher","unstructured":"Shi Y, Lin P, Ho EY, Nock CJ. Nivolumab-associated nausea and vomiting as an immune adverse event. Eur J Cancer. 2017;84. \nhttps:\/\/doi.org\/10.1016\/j.ejca.2017.07.029.","DOI":"10.1016\/j.ejca.2017.07.029"},{"key":"298_CR51","doi-asserted-by":"publisher","unstructured":"Jedli\u010dkov\u00e1 H, Vokurka S, Vojt\u00ed\u0161ek R, Male\u010dkov\u00e1 A. Alopecia and hair damage induced by oncological therapy. Klinicka Onkologie. 2019;32(5). \nhttps:\/\/doi.org\/10.14735\/amko2019353.","DOI":"10.14735\/amko2019353"},{"key":"298_CR52","doi-asserted-by":"publisher","unstructured":"Ogawara D, Soda H, Ikehara S, et al. Nivolumab infusion reaction manifesting as plantar erythema and pulmonary infiltrate in a lung cancer patient. Thorac Cancer. 2017;8(6). \nhttps:\/\/doi.org\/10.1111\/1759-7714.12494.","DOI":"10.1111\/1759-7714.12494"},{"key":"298_CR53","doi-asserted-by":"publisher","unstructured":"Saxena P, Singh PK, Malik PS, Singh N. Immunotherapy alone or in combination with chemotherapy as first-line treatment of non-small cell lung cancer. Curr Treat Options Oncol. 2020;21(8). \nhttps:\/\/doi.org\/10.1007\/s11864-020-00768-2.","DOI":"10.1007\/s11864-020-00768-2"}],"container-title":["Journal of the Egyptian National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-025-00298-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43046-025-00298-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-025-00298-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,13]],"date-time":"2025-07-13T23:02:19Z","timestamp":1752447739000},"score":1,"resource":{"primary":{"URL":"https:\/\/jenci.springeropen.com\/articles\/10.1186\/s43046-025-00298-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,14]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["298"],"URL":"https:\/\/doi.org\/10.1186\/s43046-025-00298-8","relation":{},"ISSN":["2589-0409"],"issn-type":[{"value":"2589-0409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,14]]},"assertion":[{"value":"5 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Birzeit University (reference number: BZU-PNH-2305). Personal information was not collected, and participants\u2019 identities remained unknown. All the collected information was used for research purposes. The research was performed in accordance with relevant guidelines and regulations. The Birzeit Ethical Committee did not require consent to participate in the study because this was a retrospective study conducted by collecting data from medical charts.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40"}}